<DOC>
	<DOCNO>NCT00431067</DOCNO>
	<brief_summary>The primary objective trial explore efficacy BIBW 2992 HER2 positive metastatic breast cancer patient failure trastuzumab containing regimen .</brief_summary>
	<brief_title>Phase II Trial BIBW 2992 Patients With HER2-positive Metastatic Breast Cancer After Failure Trastuzumab Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient confirm diagnosis Stage IIIB IV HER2positive metastatic breast cancer ( HER2 2+ FISH positive HER2 3+ ) . 2 . Patients must progress follow receipt prior standard trastuzumab treatment standard chemotherapy conjunction trastuzumab . Patients visceral disease rapid progression include previous chemotherapy addition trastuzumab . Patients intolerant trastuzumab receive adequate chemotherapy and/or hormone therapy eligible upon progression . 3 . Age 18 year old . 4 . Life expectancy least four ( 4 ) month . 5 . Written inform consent consistent ICHGCP guideline . 6 . Eastern Cooperative Oncology Group ( ECOG , R010787 ) performance Score 0 , 1 2 . 7 . Patients receive treatment chemotherapy immune therapy within last 4 week ( 2 week trastuzumab ) . Patients receive treatment hormone therapy within last 2 week . 8 . Patients must recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapies CTC less equal Grade 1 . 9 . Patients must recover previous surgery . 10 . Patients must measurable disease define RECIST criterion . Exclusion criterion : 1 . Active infectious disease . 2 . Gastrointestinal disorder may interfere absorption study drug chronic diarrhea . 3 . Serious illness concomitant nononcological disease consider investigator incompatible protocol . 4 . Patients active/symptomatic brain metastasis . Patients history treat brain metastasis must stable normal MRI scan screening least three month postradiation surgery . 5 . Cardiac leave ventricular function rest ejection fraction &lt; 50 % . 6 . Absolute neutrophil count ( ANC ) less 1500 cells/mm3 . 7 . Platelet count less 100 000 cells/mm3 . 8 . Bilirubin great 1.5 mg/dl ( &gt; 26 micromol /L , SI unit equivalent ) . 9 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great three time upper limit normal . 10 . Serum creatinine great 1.5 mg/dl ( &gt; 132 micromol/L , SI unit equivalent ) . 11 . Women men ( partner ) sexually active unwilling use medically acceptable method contraception . 12 . Pregnancy breastfeed . 13 . Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( include LHRH agonist , hormone take breast cancer ) , participation another clinical study within past 4 week start therapy concomitantly study . Treatment bisphosphonates allow . 14 . Prior treatment EGFR HER2 inhibit drug ( except trastuzumab ) . 15 . Patients unable comply protocol . 16 . Active alcohol drug abuse . 17 . Patients history malignancy ( except appropriately treat superficial basal cell skin cancer surgically cure cervical cancer situ ) unless free disease least 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>